Latest From AntiCancer Inc.
A US district court has granted a motion filed by Sun Pharma for partial summary judgement in its three-year battle over Lilly's Gemzar (gemcitabine HCl for injection) – invalidating Lilly's method-of-use patent (the '826 patent), which includes paediatric exclusivity and is set to expire in May 2013.
The High Court in Delhi, India has indicted Bayer for "speculative" litigation in a case concerning Cipla's marketing application for a generic version of the anticancer sorafenib tosylate.
The Delhi High Court has indicted Bayer for attempting to use "speculative" litigation in India, in a case concerning Cipla's application to introduce a generic version of Bayer's anticancer Nexavar (sorafenib tosylate).
Amgen's EGFR-targeted human monoclonal antibody, Vectibix (panitumumab), met one of its co-primary endpoints, progression-free survival (PFS), but not the other, overall survival, in patients with KRAS wild-type metastatic colorectal cancer (mCRC) in the pivotal Phase III "181" trial testing it as second-line therapy.
- In Vitro Diagnostics
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- AntiCancer Inc.
- Senior Management
Robert M Hoffman, PhD, Pres. & CEO
Charlene M Cooper, VP, COO
- Contact Info
Phone: (858) 654-2555
7917 Ostrow St.
San Diego, CA 92111
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.